Liquidia Co. (NASDAQ:LQDA - Get Free Report) General Counsel Russell Schundler sold 16,393 shares of the company's stock in a transaction that occurred on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $193,109.54. Following the transaction, the general counsel now owns 573,478 shares in the company, valued at $6,755,570.84. The trade was a 2.78 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.
Russell Schundler also recently made the following trade(s):
- On Monday, December 2nd, Russell Schundler sold 1,063 shares of Liquidia stock. The stock was sold at an average price of $11.51, for a total transaction of $12,235.13.
Liquidia Price Performance
NASDAQ:LQDA traded down $0.40 during mid-day trading on Tuesday, reaching $11.36. 552,977 shares of the company's stock traded hands, compared to its average volume of 728,753. Liquidia Co. has a 12-month low of $8.26 and a 12-month high of $16.99. The firm has a market capitalization of $961.48 million, a price-to-earnings ratio of -6.97 and a beta of 0.23. The company has a 50 day moving average price of $11.18 and a 200-day moving average price of $11.02.
Analyst Ratings Changes
A number of brokerages have commented on LQDA. Scotiabank assumed coverage on shares of Liquidia in a research note on Wednesday, October 16th. They issued a "sector outperform" rating and a $30.00 price target for the company. HC Wainwright reissued a "buy" rating and issued a $29.00 target price on shares of Liquidia in a report on Thursday, November 14th. Lifesci Capital assumed coverage on shares of Liquidia in a research report on Thursday, October 3rd. They set an "outperform" rating and a $30.00 price objective for the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $19.00 price objective on shares of Liquidia in a research note on Thursday, January 9th. Finally, Wells Fargo & Company assumed coverage on shares of Liquidia in a research note on Friday, December 20th. They set an "overweight" rating and a $20.00 target price on the stock. One research analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $25.38.
Get Our Latest Stock Analysis on Liquidia
Institutional Trading of Liquidia
A number of hedge funds have recently made changes to their positions in LQDA. Quest Partners LLC bought a new position in Liquidia in the 2nd quarter valued at approximately $27,000. Clear Harbor Asset Management LLC purchased a new stake in shares of Liquidia in the 3rd quarter worth $100,000. Signaturefd LLC increased its stake in shares of Liquidia by 38,400.0% in the 3rd quarter. Signaturefd LLC now owns 10,010 shares of the company's stock worth $100,000 after purchasing an additional 9,984 shares in the last quarter. Ballentine Partners LLC purchased a new stake in shares of Liquidia in the 3rd quarter worth $110,000. Finally, Whitcomb & Hess Inc. boosted its holdings in Liquidia by 10.2% in the 3rd quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company's stock worth $116,000 after buying an additional 1,074 shares during the period. 64.54% of the stock is owned by institutional investors.
About Liquidia
(
Get Free Report)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Liquidia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Liquidia wasn't on the list.
While Liquidia currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
